Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Overview of Labcorp Holdings Inc (LH)
Labcorp Holdings Inc is a comprehensive provider of clinical diagnostics and laboratory services, renowned for its decades of scientific expertise and innovation in medical testing. Operating in diverse segments including routine clinical tests, precision oncology, and genomic profiling, Labcorp offers a wide array of laboratory services essential for improved patient care and informed therapeutic decisions. Integrated testing solutions and advanced diagnostic capabilities are at the heart of its operations, underscoring its role as a central partner for physicians, hospitals, and biopharmaceutical companies.
Comprehensive Laboratory Services and Expertise
At its core, Labcorp specializes in high-quality, timely laboratory testing that covers a vast range of assays—from routine blood and urine screens to complex molecular and genetic tests. Its sophisticated laboratory network is equipped with state-of-the-art technologies that enable advanced clinical and anatomic pathology, esoteric testing, and genomic sequencing. This strategic application of scientific innovations ensures that the company consistently delivers accurate and actionable results, which are crucial for diagnostic precision and personalized healthcare.
Integrated Business Model and Operational Excellence
Labcorp generates revenue through a diversified business model that includes direct sales of clinical tests, integrated services for research and drug development, and strategic partnerships with healthcare providers and biopharma organizations. The company leverages its deep scientific expertise to offer high-volume diagnostic services through numerous patient-service centers and central laboratories worldwide. With decades of experience, Labcorp continuously adapts its processes to integrate advances in automation, data analytics, and digital health solutions, thereby streamlining operations and enhancing test reliability.
Precision Oncology and Genomic Profiling
A core area of Labcorp’s expertise is in precision oncology, where the company employs advanced genomic profiling techniques to support targeted cancer therapies. Its extensive portfolio of precision oncology assays, including liquid biopsy tests and tissue-based genomic profiling, enables healthcare providers to obtain critical insights into tumor biology. This capability not only supports personalized treatment strategies but is also instrumental for biopharmaceutical research and the development of innovative cancer therapies.
Serving a Broad Healthcare Ecosystem
Labcorp’s client base spans across physician offices, hospitals, managed care organizations, and pharmaceutical companies. Its services are fundamental to multiple aspects of healthcare delivery, from routine patient care to cutting-edge research initiatives. By offering an extensive range of diagnostic tests and integrated solutions, Labcorp plays a pivotal role in enabling evidence-based clinical decisions and supporting complex drug development processes.
Scientific Innovation and Industry Leadership
Labcorp is recognized for its rigorous commitment to quality and scientific precision, underscored by its continuous investment in research and technological advancements. The company’s expertise in areas such as esoteric testing, clinical genomics, and comprehensive disease profiling positions it as a trusted resource in the landscape of modern diagnostics. By harmonizing clinical insight with innovative laboratory methods, Labcorp ensures that its service offerings remain both cutting-edge and reliable.
Operational Reach and Global Impact
With a vast network of laboratories and patient-service centers, Labcorp ensures that a broad population is served with high-quality clinical diagnostics. Its operations extend globally, reflecting a commitment to improving health outcomes through widespread access to advanced testing services. The integration of technology and analytics supports its operational excellence, ensuring robust and consistent test results that are critical for clinical decision-making worldwide.
Commitment to Quality and Trust
Labcorp’s longstanding reputation is built on a foundation of expertise, stringent quality controls, and continuous innovation. The company adheres to rigorous clinical and regulatory standards, ensuring that every test meets the highest levels of accuracy and reliability. This trustworthiness, combined with its continuous advances in technology, reinforces Labcorp’s role as a key partner in the healthcare and life sciences sectors.
In summary, Labcorp Holdings Inc stands out through its broad portfolio of diagnostic solutions, deep scientific expertise, and a robust network that spans across critical sectors of healthcare. Its commitment to integrating advanced technology with clinical precision positions it as a highly reliable entity in the competitive landscape of laboratory services without resorting to speculative future claims.
Labcorp (NYSE: LH) has launched a groundbreaking blood-based biomarker test nationwide to aid in Alzheimer's disease diagnosis. The pTau-217/Beta Amyloid 42 Ratio test offers results comparable to PET imaging and CSF testing, with 95% sensitivity and specificity.
This innovative immunoassay measures two distinct biomarkers: pTau-217 and Beta Amyloid 42 in ratio, meeting performance criteria to confirm amyloid pathology consistent with Alzheimer's. The test is available at physician offices and Labcorp's 2,000+ Patient Service Centers nationwide, offering a less invasive alternative to current diagnostic methods.
With 6.9 million Americans living with Alzheimer's and diagnosis typically taking 2.8 years from symptom onset, this breakthrough aims to accelerate the diagnostic process. The test is available for both clinical trials and patient care, with data presentation scheduled at the American Association of Neurology's 2025 Annual Meeting in San Diego.
Labcorp (NYSE: LH) announced nationwide rollout of FDA-approved self-collection solutions for HPV and STI testing, available from April 7, 2025. The service will be accessible at over 2,200 Patient Service Centers and participating physician offices across the US.
The initiative addresses critical healthcare gaps, as one in four women are not up-to-date with cervical cancer screenings. With over 13,000 women diagnosed with cervical cancer annually and approximately 4,000 deaths, this preventable disease remains a significant concern. The self-collection option includes testing for HPV and STIs (chlamydia, gonorrhea, trichomonas, and mycoplasma genitalium).
Key features include:
- Physician-ordered testing with private collection options
- Available at 2,200 Labcorp PSC locations
- Electronic results delivery to both physician and patient
- Follow-up with physician required for positive results
Labcorp (NYSE: LH) has announced it will release its first quarter 2025 financial results before market opening on Tuesday, April 29, 2025. The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the results.
Investors can access the earnings release and financial information on Labcorp's Investor Relations website. The webcast will be available in listen-only mode, with participants recommended to join 10 minutes before the start. A replay of the webcast will be accessible approximately two hours after the event concludes and remain available until April 16, 2026.
Labcorp (NYSE: LH) has announced an agreement to acquire select assets of BioReference Health's oncology and oncology-related clinical testing services from OPKO Health. The transaction, valued at up to $225 million, includes $192.5 million at closing and a potential $32.5 million performance-based earnout.
The acquired assets generate $85-100 million in annual revenue and will expand Labcorp's oncology diagnostic testing portfolio across the United States. The deal is expected to be earnings accretive in the first year and close in the second half of 2025.
Post-acquisition, BioReference Health will maintain its core clinical testing operations in the New York and New Jersey region, including its 4Kscore franchise, which generated approximately $300 million in revenue for 2024.
Labcorp (NYSE: LH) has announced the clinical availability of Labcorp® Plasma Complete™, a liquid biopsy test for comprehensive genomic profiling in patients with advanced solid tumors. The test analyzes circulating tumor DNA (ctDNA) from a simple blood draw, detecting genomic alterations across 521 genes, including various mutations, amplifications in 12 genes, and translocations associated with 12 genes.
The test features high sensitivity with variant detection as low as 0.1% and specificity exceeding 99.99%. It provides insights for FDA-approved therapies, guideline-driven treatments, and clinical trial eligibility. The solution has been validated in Labcorp's CAP-accredited and CLIA-certified laboratory, with validation studies published in the Journal of Molecular Diagnostics confirming its clinical accuracy.
Labcorp (LH) reported strong Q4 and full-year 2024 results, with Q4 revenue reaching $3.33 billion (up 9.8% YoY) and full-year revenue of $13.01 billion (up 7.0% YoY). The company's Q4 diluted EPS improved to $1.70 from $(1.95) last year, while adjusted EPS increased to $3.45 from $3.30.
Free cash flow showed significant improvement, with Q4 at $665.1 million (up from $412.4 million) and full-year at $1.10 billion (up from $748.7 million). The company completed 10 transactions in 2024 and launched new innovative tests in specialty areas.
For 2025, Labcorp projects revenue between $13.88-14.05 billion (7.4% growth at midpoint), adjusted EPS of $15.60-16.40 (9.8% growth at midpoint), and free cash flow of $1.10-1.25 billion (7.2% growth at midpoint).
Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, January 14, at 3:45 p.m. Pacific Time.
Interested parties can access a live audio webcast of the discussion through Labcorp's Investor Relations website at ir.Labcorp.com. The session will also be archived for future viewing.
Labcorp (NYSE: LH) has announced a quarterly cash dividend of $0.72 per share of common stock. The dividend will be distributed on March 12, 2025, to stockholders recorded as of the close of business on February 27, 2025. This announcement comes from the global leader in innovative and comprehensive laboratory services, following a declaration by its Board of Directors.
Labcorp (NYSE: LH) has announced it will release its fourth quarter 2024 financial results before market opens on February 6, 2025. The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the results.
The earnings release and financial information will be available on Labcorp's Investor Relations website. Participants can join the listen-only webcast and conference call through registration, with recommended arrival 10 minutes before start time. A replay of the webcast will be accessible approximately two hours after the event and remain available until January 24, 2026.
Geneoscopy has successfully closed a $105 million Series C funding round, led by Bio-Rad Laboratories (NYSE: BIO). The funding will support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease.
The investment round included participation from notable investors including Petrichor, Labcorp, Morningside Ventures, and others. Geneoscopy's technology combines RNA isolation from stool samples with Bio-Rad's Droplet Digital™ PCR technology for effective cancer screening. Through a partnership with Labcorp, ColoSense will be made widely available to healthcare providers.
This funding follows FDA approval of ColoSense and aims to address the rising incidence of colorectal cancer, particularly among people under 50. The test offers a non-invasive alternative to traditional colonoscopies, potentially increasing screening accessibility for millions of eligible individuals who currently avoid testing.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
What core services does Labcorp Holdings Inc provide?
How does Labcorp generate its revenue?
What distinguishes Labcorp in the marketplace?
How does Labcorp support precision oncology?
Who are the main customers of Labcorp?
What role does innovation play at Labcorp?
How extensive is Labcorp’s network of laboratories?
How does Labcorp integrate technology with healthcare services?
